Tinkelman D G, Berkowitz R B
Atlanta Allergy Clinic, GA 30328.
Ann Allergy. 1991 Feb;66(2):162-5.
Pemirolast is a potent, long-acting, orally effective antiallergic agent evaluated for clinical activity in prevention of symptoms of seasonal allergic rhinitis. It was evaluated in a randomized, double-blind, placebo-controlled parallel group in season trials to test its safety, tolerance, and prophylactic activity. Thirty-one patients with a history of fall seasonal allergic rhinitis were treated for 6 weeks with pemirolast, 50 mg bid, or placebo beginning approximately 2 weeks before the onset of the ragweed season in Atlanta. Daily evaluation of symptom scores disclosed statistically significantly less sneezing, rhinorrhea, and stuffy nose during treatment with pemirolast. There was, however, no difference for other evaluated symptoms or for the use of rescue medicines. There were no side effects during this short study. This preliminary study indicates that pemirolast may warrant further evaluation for the treatment of allergic rhinitis.
吡嘧司特是一种强效、长效、口服有效的抗过敏药物，已对其预防季节性变应性鼻炎症状的临床活性进行了评估。在季节性试验中，采用随机、双盲、安慰剂对照平行组对其安全性、耐受性和预防活性进行了测试。31例有秋季季节性变应性鼻炎病史的患者，在亚特兰大豚草季节开始前约2周，接受吡嘧司特（50mg，每日2次）或安慰剂治疗6周。每日症状评分评估显示，吡嘧司特治疗期间打喷嚏、流涕和鼻塞的症状在统计学上显著减轻。然而，在其他评估症状或使用急救药物方面没有差异。在这项短期研究中没有副作用。这项初步研究表明，吡嘧司特可能值得进一步评估用于治疗变应性鼻炎。
